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High-risk human papillomavirus types, especially type 16, are risk factors for cervical cancer. Preliminary studies suggest that
HPV16 polymorphisms in the long control region or in the E6 gene may alter the oncogenic potential of the virus. This could
partially explain why some lesions progress to cancer while others do not. A systematic study combining the long control
region and E6 has not been undertaken. This prompted us to investigate the long control region and the E6 in northern
European women infected with human papillomavirus 16. We identiﬁed the sequence variations of both regions and
investigated the long control region promoter activity among various isolates. In addition, we correlated the distribution of long
control region and E6 polymorphisms with disease status. We analyzed 45 samples from Swedish and Finnish women. The
long control region and the E6 gene were sequenced after polymerase chain reaction long control region fragments of six
European isolates covering the majority of polymorphisms in this region were ligated into the pALuc vector and used for
luciferase assays. In European HPV16 isolates, polymorphisms in the long control region are more frequent than in the E6
gene. Nevertheless, the promoter function was slightly increased in only one of the tested European long control region
variants. In addition, we found a speciﬁc European E6 variant, L83V, to be enriched in high-grade lesions and cancer rather
than a speciﬁc European long control region variant. The difference in oncogenicity between European HPV16 genotypes is
more probably due to an altered property of the corresponding E6 proteins rather than to an altered activity of the P97
promoter.
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High-risk human papillomaviruses (HPVs), especially of type 16, are
considered to be the most important risk factors in the development
of cervical neoplasias (zur Hausen, 1991; Walboomers et al, 1999).
However, only a fraction of women with HPV16-positive cervical
precursor lesions develop cancer. The viral oncoproteins E6 and E7
are responsible for the malignant transformation of cervical epithe-
lium by interacting with cell cycle-regulating proteins e.g. p53 and
pRb (Scheffner et al, 1990; Phelps et al, 1992). The transcription of
E6 and E7 genes is controlled by the P97 promoter located in the
E6 proximal part of the long control region (LCR), which contains
the keratinocyte speciﬁc enhancer as well as several binding sites
for cellular and viral transcription factors (Chong et al, 1991).
Sequence variations within the LCR and/or E6 and E7 genes may
therefore have an impact on the oncogenic potential of the virus.
The HPV16 genome is polymorphic with respect to geographical
regions giving rise to European, African, Asian, Asian-American
and north American subtypes. These can be further divided into
multiple genotypes (Yamada et al, 1997). The originally identiﬁed
reference sequence, the so-called prototype (Seedorf et al, 1985),
belongs to the European subtype (Yamada et al, 1997). It was
reported that the promoter activity of Asian-American and north
American HPV16 variants is increased three-fold as compared to
the prototype (Ka ¨mmer et al, 2000) and that polymorphisms in the
E6 gene but not in the E7 gene correlate with the severity of the lesion
in several European populations (Zehbe et al, 1998a,b). So far, no
investigation has systematically compared LCR sequence variations
with the transcriptional efﬁciency of the LCR promoter in combina-
tion with E6 polymorphisms and their association with cervical
disease status in a larger group of clinical samples.
The objective of this study was to determine the LCR and the E6
sequences of HPV16 from north European women and to establish
whether there are differences in promoter activity between the
genotypes thus identiﬁed. In addition the distribution of poly-
morphisms in the LCR and in the E6 was correlated with disease
status. We found polymorphisms in the LCR to be more common
than polymorphisms in the E6 gene in European isolates. However,
the promoter function was similar in six representative isolate
types, except for one. In addition, no speciﬁc European LCR
variant was associated with progression or higher lesion grade,
while an E6 variant was found to be enriched in high-grade lesions
and cancer. This E6 variant showed an amino acid change from
leucine to valine at residue 83 (L83V). We conclude that the differ-
ent oncogenicity between European HPV16 genotypes is more
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protein rather than by an altered activity of the P97 promoter.
SUBJECTS AND METHODS
Subjects
Clinical samples Altogether 45 HPV16-positive specimens from
20 Swedish and 25 Finnish women were included in the study. The
Swedish samples are derived from a cross-sectional study consisting
of extracted DNA from formalin-ﬁxed cervical biopsies diagnosed
as having low-grade or high-grade cervical intraepithelial neoplasia
(LCIN, HCIN) or invasive cervical carcinoma (ICC) (Zehbe et al,
1998b, 2001a). The Finnish samples are derived from a follow-up
study consisting of DNA from frozen cervical biopsies with known
endpoint diagnosis, i.e. LCIN or HCIN (Kurvinen et al, 2000).
Consequently, the analysis of the present investigation of the E6
gene was performed on all samples where sufﬁcient material was
still available. Of the Swedish women, the E6 sequences have
previously been reported (Zehbe et al, 1998b, 2001a) and of the
Finnish women the LCR sequences have previously been described
(Kurvinen et al, 2000).
Methods
PCR, sequencing, and plasmid constructs of the LCRs The
LCR region from the Swedish samples was ampliﬁed by nested
PCR (LCR-6933 5'-CACCTCCAGCACCTAAAGAAGATCCCC-3',
LCR-140 5'-GCAGCTCTGTGCATAACTGTGG-3', LCRHind-7010
5'-ATCAAGCTTGACCTAGATCAGTTTCCTTTAGGAC-3', LCR
Bam-124 5'-ATCGGATCCTCCTGTGGGTCCTGAAACATTGCAG-
3') generating fragments ranging from nucleotide (nt) positions
7010 to 124 with the inner primers containing HindIII and BamHI
restriction sites (Dong et al, 1994). The puriﬁed LCR fragments
were ligated into the precut vector pALuc (Dong et al, 1994), so
that the P97 promoter of the LCRs was placed in front of the luci-
ferase reporter gene. Before using them in luciferase assays the
different pALuc-clones were sequenced.
PCR and sequencing of the HPV 16 E6 The HPV16 E6-speci-
ﬁc PCR amplifying the region spanning nucleotides (nts) 52–575
and the sequencing reactions of the Finnish samples were
performed as described earlier (Zehbe et al, 1998b).
Cell culture and functional assays of the LCR constructs The
HPV-negative human cervical carcinoma cell line C33A (ATCC
HTB-31) was used for luciferase experiments performed as
described earlier (Kammer et al, 2000).
Site directed mutagenesis with the LCR constructs Site direc-
ted mutagenesis was performed with the US56 clone using the
QuickChange Site-Directed Mutagenesis-Kit supplied by Strata-
gene. The nucleotide at position 78 (US56) was changed from
the isolate sequence into the European reference sequence (m-
US56). The sequence variation of the US56 isolate at position 78
was introduced into the European reference sequence (m-E/
US56). The primers used comprised 34 bp from nt 57–89 and
contained the intended nucleotide exchange. After obtaining posi-
tive clones the whole LCRs were sequenced to conﬁrm the mutated
nucleotide in the context of the former LCR sequences.
RESULTS
The LCR is more polymorphic than the E6 gene in
European HPV16 genotypes
After PCR, the entire HPV16 LCR (nts 7010–124) and the entire
HPV16 E6 gene (nts 83–559) were sequenced and compared with
the European reference sequence (HPV16R sequence in the HPV
database). The sequences of all samples tested in the present investi-
gation are summarized in Figure 1.All 45 isolates could beassigned to
the European group (Yamada et al, 1997). The LCR of European
genotypes is more polymorphic than the E6 gene. In the LCR,
32 nt substitutions were characterized, while in the E6 gene, seven
different polymorphisms were identiﬁed, six of them leading to
amino acid changes. The distribution of LCR and E6 polymorphisms
in HPV16-infected Finnish women resembles approximately that
found in the Swedish population (Zehbe et al, 1998b). In the LCR
the nt changes at positions 7193 and 7521 (51%) were most
frequently detected and in the E6 gene, L83V was most frequently
detected (67%). LCR-7193/7521 and E6-L83V were found together
in 15 cases (33%) and prototype sequences in both regions were
present in seven cases (16%). Consequently, 23 cases (51%) showed
a linkage disequilibrium between the E6 and LCR sequences.
Alteration in promoter activity among European LCR
genotypes is a rare event
We next performed functional studies to elucidate whether speciﬁc
HPV16 LCR genotypes, detected in north European women, differ
in their promoter activity. Most isolates in our tested group
contained polymorphisms in their LCR sequence as compared with
the reference sequence (Figure 1). Some of these were identiﬁed
within transcription factor-binding sites, which might modulate
viral promoter activity positively or negatively (Table 1) (Kurvinen
et al, 2000). To examine a representative set of samples, we
included the frequently detected LCR-7193/7521 (US53, identical
with isolate 59 of Veress et al (1999)) as well as samples with addi-
tional changes in transcription factor-binding sites, i.e. US50, 17
and 134 (Table 1). In addition, US56 was included since it contains
a variation, which has not previously been described, namely at nt
78 (Table 1). Finally, we tested US58 because the change at posi-
tion 7225 was found three times in our analysis (US42, 58 and
97a; Figure 1).
The HPV16 LCRs were cloned into the pALuc vector in front of
the luciferase gene in order to determine whether the above-
mentioned sequence alterations affect the P97 promoter activity.
C33A cells were transfected with the isolate constructs and lucifer-
ase activities were analyzed 48 h later. All isolates, except US56,
exhibited approximately the same activity as the European refer-
ence clone with transcription activities ranging from 0.87 to 1.27
(Figure 2). The US56 isolate showed a stimulation of 2.2-fold
compared to the European reference clone (Figure 2).
To determine whether the newly identiﬁed sequence alteration at
position 78 (US56) was responsible for the 2.2-fold increase in P97
promoter activity, site directed mutagenesis was performed. US56
exhibited altogether four sequence variations but only one singular
to this clone, namely the G4A transition at nt position 78. This
position was mutated back into the European reference sequence,
creating m-US56. The same nucleotide variation was introduced
into the European reference clone creating m-E/US56. Subse-
quently luciferase assays were performed with the variants and
their mutated counterparts. The transcriptional activity of the
P97 promoter of m-US56 dropped to a level comparable with
the European reference, whereas m-E/US56 exhibited an increase
(1.73), thus indicating that indeed this nucleotide exchange is
important for the regulation of the P97 promoter activity (Figure
2).
Together, these and previously published results clearly show
that most LCR polymorphisms do not cause a change in promoter
activity. Indeed, when considering all LCR isolates tested thus far
(Veress et al, 1999) only one of a total of eight identiﬁed European
LCR variants revealed an increased promoter activity compared to
the prototype. Interestingly, the change in promoter activity could
be singled out to just one nt exchange being an A to G change at
position 78.
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HPV16 genotypes correlate with disease status
We next determined, whether the most frequently detected geno-
types, LCR-7193/7521 and E6-L83V, correlate with disease status.
No change in promoter activity has been observed with LCR-7193/
7521 compared to the prototype. With these results in hand, one
would not expect LCR-7193/7521 to correlate with disease status.
E6-L83V, on the other hand, has previously been shown to be asso-
ciated with high-grade lesions and cancer in Swedish women and
Norwegian women (Zehbe et al, 1998b; Andrew Jenkins, personal
communication). In the Finnish group, E6-L83V was associated with
progression in 50% of the cases, whereas the same genotype was
present in only 20% of the regressing lesions. In contrast, the preva-
lence of 7193/7521 irrespective of the E6 polymorphism was similar
in regressing and in progressing lesions with known endpoint diagno-
sis, being 60 and 67%, respectively (data not shown). Since the
association of L83V with disease status is similar in Swedish and
Finnish women, the data of the twogroups were pooled in the current
study. A statistically signiﬁcant trend for an increased prevalence of
E6-L83V with increasing severity of the lesion (P=0.04) was observed,
while this was not the case for LCR-7193/7521 (P=0.15) (Table 2).
These results indicate that certain E6 polymorphisms rather than
LCR polymorphisms are associated with disease status in women
infected with European HPV16 genotypes. This may reﬂect a differ-
ence in oncogenicity between European HPV16 genotypes, which is
caused by an altered property of the various E6 proteins rather than
to an altered activity of the P97 promoter.
DISCUSSION
In the present study, we have established the LCR sequences of
HPV16 genotypes and compared the viral P97 promoter activity
in a sub-set of the isolates detected. In addition, we assessed the
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Figure 1 Sequence alterations relative to the LCR and E6 open reading frame of reference HPV16. Differences between the isolates and the HPV16
reference sequence (bold) are shown. The type of lesion from which the isolates are derived is indicated. Dashes indicate nucleotides identical to the re-
ference sequence. Capital letters indicate alterations in the E6 open reading frame that result in amino acid changes, while lower case letters indicate silent
mutations. The position of amino acid change is indicated numerically. The letter preceding this number refers to the prototype amino acid, and the letter
following it refers to its substitution. The polymorphisms not reported previously appear in italics. Swedish cases are denoted ‘US’ and Finnish cases ‘F’ or ‘T’.
HPV=human papillomavirus; LCR=long control region; ORF=open reading frame; R=reference sequence (Seedorf et al, 1985); L/HCIN=low-grade/high-
grade cervical intraepithelial neoplasia.
Table 1 Variations in LCR sequences within proposed or known tran-
scription factor-binding sites of the tested clones. Only nucleotide
changes within a transcription factor site are given of the respective
LCR sequence. All changes found in a particular clone are shown in
Figure 1
Transcription
factor-binding
Nucleotide US50 US17 US134 US56 site
7216 T G GRE/1
7310 C G G NF-IL6
7394 C T GRE/1
78 A G YY1
GRE=glucocorticoid/progesterone response element; NF-IL6=nuclear factor for
interleukin 6; YY1=Yin and Yang factor 1.
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(2), 269–273signiﬁcance of LCR and E6 polymorphisms for the clinical
outcome of cervical disease in Swedish and Finnish women. All
cases of our samples could be assigned to the European subtype.
The LCR region of European HPV16 genotypes is more poly-
morphic than the E6 gene in our samples. In half of the
samples, the LCR and the E6 sequences were in linkage disequili-
brium. In spite of the variability of the LCR even within known
or proposed transcription factor-binding sites, LCR polymorphisms
appear not to inﬂuence the fate of the disease in women infected
with European variants, while we could show in the present and
in previous investigations that this, indeed, is the case with speciﬁc
European HPV16 E6 genotypes. This is underlined by the fact that
most European LCR genotypes analyzed to date have a promoter
activity comparable to the reference isolate (Veress et al, 1999; this
study). So far, only one variation, namely at position 78 within a
YY1-binding site (O’Connor et al, 1996) with a change from A
to G was found to be responsible for a two-fold increase of the
promoter activity when compared with the prototype. Interestingly,
after a more extensive mutagenesis from CAT to TGC (nts 77–79),
no effect on promoter activity was observed (O’Connor et al,
1996). This may be due to a change in binding of another factor
to this site acting as a mild activator. The 78 variant was detected
only once in our study group and has not previously been
described in clinical samples. Notably, other alterations within
transcription factor sites identiﬁed in the present investigation
(Table 1) did not change promoter activity. The HPV16 E6-L83V
variant, on the other hand, is the most common E6 variant in
north European women and correlates statistically with the severity
of cervical disease in three Scandinavian countries, i.e. Finland,
Sweden and Norway (Zehbe et al, 1998b; Kurvinen et al, 2000;
Andrew Jenkins, personal communication). The reason for this is
probably not due to functional differences of the E6 protein but
rather to the fact that this particular viral protein evades host
immune recognition (Zehbe et al, 2001b). This is further under-
lined by the fact that the oncogenicity of viral variants seems to
be related to the geographical area studied. For instance, E6-
L83V is not enriched in Italian or Czech women with cancer.
Instead, other E6-genotypes are found to be associated with cancer
in these women (Zehbe et al, 2001b). In addition, E6-L83V is
evenly distributed in precursor lesions and cancer in a German
study (Nindl et al, 1999).
While European LCR isolates do not differ a great deal in their
promoter activity, this is not the case with LCR variants of the
Asian-American and north American lineages. Interestingly, all
genotypes within these two branches contain the nucleotide
exchange at position 7729, which is responsible for a three-fold
increased activity of the P97 promoter compared to the reference
isolate (Kammer et al, 2000). This nt exchange is not present in
African or European genotypes. A statistically signiﬁcant associa-
tion was observed between non-European LCR variants
containing this polymorphism and disease status in a study of
women from Costa Rica (Hildesheim et al, 2001). Similar results
were obtained in a Brazilian and in a north American study (Xi
et al, 1997; Villa et al, 2000). Moreover, we could show that in
Italian women, the Asian-American variant had a nine-fold higher
prevalence in cervical cancer than in low-grade precursor lesions
(Zehbe et al, 2001b ) and in the Finnish group the one case
infected with this variant progressed (Kurvinen et al, 2000).
In summary, the oncogenic potential of Asian-American or
north American lineages is inﬂuenced by polymorphisms in the
LCR and possibly in other viral genome regions. In contrast, in
the European lineage this phenomenon appears to be associated
with E6 rather than LCR variations.
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Figure 2 Luciferase expression under the control of the HPV16 LCR-fragments of the different European isolates The results for the isolates US53, 50,
17, 134, 56 and 58 as well as the mutated LCR m-US56 are shown. The mean values of six independent assays together with their standard deviations are
demonstrated. The LCR of prototype HPV16 was used as a reference clone and set to the value 1.0 in all assays.
Table 2 Distribution of HPV16 E6 genotypes and LCR polymorphisms in
Swedish and Finnish women with cervical lesions
Disease status
LCIN (%) HCIN (%) ICC (%) P-value
a
E6 genotypes
L83V-like 2 (25) 16 (53) 5 (71)
Other than L83V-like 6 (67) 14 (47) 2 (29) 0.04
E6 LCR polymorphisms
7193/7521-containing 5 (63) 19 (63) 5 (71)
Others 3 (37) 11 (37) 2 (29) 0.15
aCochran-Armitage Trend test was performed using StatXact, Cytel Software.
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